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Abstract
Aims Data from patient registries give insight into the management of patients with heart failure (HF), but actual data
from unselected real-world HF patients are scarce. Therefore, we performed a cross sectional study of current HF care in
the period 2013–2016 among more than 10,000 unselected HF patients at HF outpatient clinics in the Netherlands.
Methods In 34 participating centres, all 10,910 patients with chronic HF treated at cardiology centres were included
in the CHECK-HF registry. Of these, most (96%) were managed at a specific HF outpatient clinic. Heart failure was
typically diagnosed according to the ESC guidelines 2012, based on signs, symptoms and structural and/or functional
cardiac abnormalities. Information on diagnostics, treatment and co-morbidities were recorded, with specific focus on drug
therapy and devices. In our cohort, the mean age was 73 years (SD 12) and 60% were male. Frequent co-morbidities
reported in the patient records were diabetes mellitus 30%, hypertension 43%, COPD 19%, and renal insufficiency 58%. In
47% of the patients, ischaemia was the origin of HF. In our registry, the prevalence of HF with preserved ejection fraction
was 21%.
Conclusion The CHECK-HF registry will provide insight into the current, real world management of patient with chronic
HF, including HF with reduced ejection fraction, preserved ejection fraction and mid-range ejection fraction, that will help
define ways to improve quality of care. Drug and device therapy and guideline adherence as well as interactions with age,
gender and co-morbidities will receive specific attention.
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Introduction
Chronic heart failure (HF) is an important health care prob-
lem with high cardiovascular morbidity and mortality [1].
The prevalence of HF is 1–2% in developed countries and
is expected to rise even further in the next decades [2].
Chronic HF has a disturbing prognosis if untreated or in-
sufficiently treated, while suboptimal treatment is often not
sufficiently recognised [3, 4].
We could improve the prognosis considerably when we
would optimise drug and device therapy according to the
European Society of Cardiology (ESC) guidelines [5], at
least in the patients with HF and reduced left ventricular
ejection fraction (HFrEF). Optimal treatment also includes
adequate attention to lifestyle habits and management of
co-morbidities. Considering medication, a guideline-based
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approach directly enhances the quality of care delivered to
HF patients. However, older surveys such as the EuroHeart
survey showed that only a minority of the patients were
treated adequately with these agents, and when consider-
ing target dose the figures are even worse [6]. More recent
surveys show much better adherence to HF treatment, but
these surveys have shortcomings such as limited represen-
tativeness of included patients or lack of information on
drug dose [7–9]. Furthermore, most studies did not distin-
guish between HFrEF and HF with preserved LVEF (HF-
pEF) [7–9]. We should consider these aspects if we want
to assess adherence to guidelines in daily practice, which
is a clear marker of quality of care delivered by health care
professionals. Suboptimal adherence to guidelines is often
claimed to be due to the presence of co-morbidities, but this
has not been sufficiently studied. Therefore, it is important
that we enhance awareness of the complexity of modern HF
care, which includes the management of co-morbidities.
For better insight into these clinically relevant aspects,
we set up a large cross-sectional study to assess current
treatment of HF patients at outpatient clinics. The aim of
the study was to describe clinical characteristics and treat-
ment of unselected patients with HF in the Netherlands.
Notably, we will evaluate how recommendations of the Eu-
ropean guidelines regarding pharmacological and non-phar-
macological treatments are adopted in clinical practice and
to find determinants of non-adherence.
The CHECK-HF study design
The CHECK-HF (Chronisch Hartfalen ESC-richtlijn Cardi-
ologische praktijk Kwaliteitsproject-HartFalen) is a Dutch
registry aimed at improving quality of HF care in the
Netherlands.
The current study is a cross-sectional registration of all
unselected patients diagnosed with chronic HF who are
treated at Dutch outpatient HF clinics (96%) in the pe-
riod September 2013–September 2016. All patients with
HF seen at the general cardiology outpatient clinic of the
same hospitals (4%) could be included as well. There are
no available data that allow us to estimate the exact propor-
tion of patients from the centres that was included in our
database. The objective was to include all enlisted patients.
In view of the estimated average number of patients per
centre the average proportion of included outpatient clinic
patients with HF is well above 80%. In total, 34 Dutch
hospitals, including 1 academic hospital agreed to partic-
ipate (Supplementary material list of participating centres
and investigators) (Fig. 1).
The ethics committee approved our study (METC 2017
– Maastricht University Medical Center, Maastricht, the
Netherlands).
Type of patients
Patient were included if the diagnosis of HF was based on
the criteria of the ESC guidelines, that is signs and symp-
toms, and structural and/or functional cardiac abnormalities
[5]. Heart failure was subtyped in HFrEF (EF< 50%) or
HFpEF (EF≥ 50%) according to the guidelines that were
in force at that time. Baseline ejection fraction assessments
by echocardiography were available for the majority of pa-
tients at inclusion, while in some this was only classified
semi-quantitatively (in a very small proportion, information
was not provided). In the patients with available % ejec-
tion fraction, the whole spectrum of LVEF according to
the new guidelines classification including the new group
of mid-range EF (HFmrEF) with an EF of 40 to 49% can
be studied [10]. No further exclusion criteria were applied
apart from age <18 years. Aetiology of HF was further de-
fined as ischaemic or non-ischaemic and further specified
as hypertensive, valvular, related to arrhythmias or other, if
applicable.
Baseline characteristics and demographics
The recorded dataset at inclusion consisted of age, sex,
length, weight, body mass index, heart rate, systolic blood
pressure, diastolic blood pressure, date of diagnosis, date
of first outpatient visit, date of inclusion, New York Heart
Association (NYHA) class, EF, HFrEF or HFpEF, pace-
maker, implantable cardioverter defibrillator (ICD) or car-
diac resynchronisation therapy (CRT), QRS duration, basic
rhythm, laboratory values (serum creatinine, urea, potas-
sium, sodium, brain natriuretic peptide (BNP), N-terminal
pro hormone BNP (NT-proBNP)), co-morbidity and partic-
ipation in cardiac rehabilitation programme.
Assessment of current medication use
The recorded dataset includes in-depth information (type,
dosage and frequency, total daily dose) of the use of
beta-blockers, angiotensin converting enzyme inhibitors
(ACE) or angiotensin receptor II antagonists (ARB), min-
eralocorticoid receptor antagonists (MRA), ivabradine,
diuretics (furosemide, bumetanide, hydrochlorothiazide,
triamterene), digoxin, amiodarone, and statins. The use of
platelet inhibitors and/or oral anticoagulants (yes/no) was
recorded as well.
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Fig. 1 The 34 participating
centres in the Netherlands
Echocardiographic parameters
At inclusion, we recorded values of the most recent echocar-
diogram of the patient with estimated ejection fraction in
percentage either by biplane Simpson or Teicholtz, or left
ventricular function semi-quantitatively assessed as normal
function or mildly, moderately or severely impaired func-
tion. In the majority of patients, quantitative values of EF
were available and recorded (73%). Diastolic function, pres-
ence of restrictive filling pattern of the left ventricle as well
as semi-quantitative assessment of inferior vena cava di-
mension/collapse, and pressure gradient across the tricuspid
values were recorded.
Co-morbidities
The recorded dataset specifically noted the presence of
co-morbidities as recorded in medical history (diabetes
mellitus, hypertension, hypercholesterolaemia, renal insuf-
ficiency (estimated glomerular filtration rate <60), anaemia
(haemoglobin below age-dependent threshold), thyroid dys-
function, chronic obstructive pulmonary disease (COPD) or
obstructive sleep apnoea, and peripheral arterial occlusive
disease).
Data inclusion
Data inclusion was performed using the CHECK-HF
database based on Microsoft Excel with Visual Basic
for Application designed to digitalise characteristics of
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Table 1 Baseline demographics in 10,910 patients with chronic heart
failure (CHECK-HF)
Baseline characteristics
Age, years (mean, SD); n= 10,890 72.8± 11.9
Gender, % male; n= 10,859 6523 (60.1%)
Body mass index, kg/m2 (mean, SD); n= 9989 27.5± 5.4
Hypertension, %; n= 9733 4173 (42.9%)
Diabetes mellitus, %; n= 9733 2877 (29.6%)
Renal insufficiencya, %; n= 8690 5055 (58.2%)
COPD, %; n= 9733 1829 (18.8%)
Aetiology: n= 10,468
Ischaemic cardiomyopathy, % 4877 (46.6%)
Non-ischaemic cardiomyopathy, % 5591 (53.4%)
Heart failure: n= 10,627
Reduced ejection fraction, % 8360 (78.7%)
Preserved ejection fraction, % 2267 (21.3%)
Unknown, % 283 (2.6%)
LVEF, % (mean, SD); n= 9178 36.0± 14.1
NYHA class; n= 10,664
I, % 1808 (17.0%)
II, % 5884 (55.2%)
III, % 2777 (26.0%)
IV, % 195 (1.8%)
Heart rate, bpm (mean, SD); n= 10,659 72.2± 14.1
Systolic BP, mm Hg (mean, SD); n= 10,664 127.6± 21.5
Heart failure outpatient clinic; n= 10,780 10,385 (96.3%)
BP blood pressure, bpm beats per minute, COPD chronic
obstructive pulmonary disease, eGFR estimated glomerular filtration
rate, HF heart failure, LVEF left ventricular ejection fraction,
MI myocardial infarction, NYHA New York Heart Association,
SD standard deviation
aDefined as eGFR below 60 or history of renal failure
patients and patient flow at the outpatient HF clinics. Each
hospital recorded their data in a uniform stand-alone online
database. Patient data were encoded and exported to a cen-
tral database, fully anonymised, and cannot be traced to an
individual patient. Data inclusion was based on a standard-
ised protocol including a set of variables. As data collection
was based on daily practice not all variables were available
in all patients.
Outcomemeasures
The main analysis will present the adherence to guide-
line-directed medication-based therapy and device-based
therapy in HFrEF patients. We will analyse adherence
as percentage (%) of prescriptions as well as percentage
(%) of target dose of guideline-recommended heart failure
treatments [5]. In addition, we will analyse the percentage
of prescribed ICD therapy and CRT defibrillator (CRT-
D) therapy. Adherence data will be presented in future
manuscripts. Secondary analyses will focus on specific
subgroups of reduced and preserved left ventricular ejec-
tion fraction (LVEF) as well as comorbidities.
Statistical analysis
Summary statistics are provided as percentages (%) or as
mean with standard deviations (SD).
Baseline continuous variables are presented as mean± SD
or median and interquartile range, depending on the distri-
bution of the data; categorical data are presented as counts
and percentages. We will compare the categorical variables
using the χ2 test and the continuous variables using the t-
test or the Mann-Whitney U-test, as appropriate. Univariate
and multivariate regression analysis will be used to calcu-
late odds ratio and 95% confidence interval. Drug dose will
be calculated compared with the recommended dose ac-
cording to guidelines as percentage of actual recommended
daily dose. Analyses are and will be performed with SPSS
system software (version 24.0 or later).
Results
Demographics of the enrolled patients can be found in
Tab. 1. About 60% were male and the average age was
73 years, with a wide range between 18 and 103 years of age
(median 75 years, interquartile range (IQR) 66–82 years).
Co-morbidities were common and in about half of the pa-
tients their HF was of ischaemic origin (46%). The vast
majority of patients had reduced left ventricular ejection
fraction (79%). Mean ejection fraction was 37% (SD 14).
Most patients were in functional NYHA class II (55%).
Discussion
The current study will evaluate current quality of HF care
in unselected patients with heart failure in the Netherlands.
The CHECK-HF registry will demonstrate current adher-
ence to ESC guidelines in the period of 2013–2016, that is
between the publications of the 2012 and 2016 guidelines
[5, 10]. Importantly, in CHECK-HF we not only collect
data on presence or absence of medication, but also on
the exact prescribed dosage. Knowledge regarding adher-
ence to current recommended treatment, including dosage,
is important as it can provide new insights on how we can
improve current prescription rates and current practice.
The current study population of chronic HF patients
in a real word setting differs from clinical trials by the
high percentage of female patients and elderly patients
and high prevalence of multiple co-morbidities. These
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categories are chronically underrepresented in clinical tri-
als, but form a significant part of the HF population seen
in daily practice. The CHECK-HF registry will evaluate
these subgroups with specific attention in secondary anal-
yses studying treatment differences or differences in co-
morbidity distribution.
The CHECK-HF registry
The CHECK-HF registry consisted of a relatively high pro-
portion of HFpEF patients (21%). As noted in previous
literature, there is a high percentage of female and/or el-
derly patients in this subgroup. The ESC guidelines had
no specific treatment recommendations for HFpEF due to
lack of evidence in randomised clinical trials. The CHECK-
HF registry will describe how these patients are treated and
evaluate the distribution of age, gender and co-morbidity
within this subgroup of HFpEF patients.
The number of co-morbid conditions in a patient with
chronic HF is high and has been increasing in the last
decade [11]. The majority of patients have 5 or more co-
morbid chronic conditions which are important determi-
nants of the number of hospital re-admissions [11]. We
can argue that in order to reduce the number of HF re-ad-
missions, we should focus on influencing the level of co-
morbidities [11]. We can also hypothesise that earlier in-
terventions could lower the extent of co-morbidities and
collateral damage. There is a variety of examples of rela-
tively simple solutions which may affect prognosis such as
iron supplementation in iron deficient HF patients. Other
examples are vitamin D deficiency, obstructive sleep ap-
noea syndrome and subclinical hypothyroidism. Secondary
analyses of the CHECK-HF registry will focus on the level
of co-morbidities in a real-world cohort and study potential
interaction with the level of co-morbidities and treatment
adherence. However, given the set-up of the CHECK-HF
registry, we only have information for a selected number of
co-morbidities.
Comparisonwith other registries
Several large national HF registries have been published
in Europe [6–9, 12–17]. In Tab. 2 we provide an example
of relevant major European HF registries with more than
thousand patients with a report on heart failure medica-
tion and/or ICD therapy in specific patients with chronic
heart failure [6–9, 12–17]. We particularly want to address
two registries. The European Society of Cardiology Heart
Failure (ESC-HF) pilot study was a prospective, multicen-
tre, observational survey conducted in 136 cardiology cen-
tres from 12 European countries selected to represent the
different health systems and care attitudes across Europe
[7]. The ESC-HF pilot 2010 included 3,226 patients with
chronic HF; mean age was 67 years and percentage of fe-
male patients was 29.7%, both figures much lower than in
the CHECK-HF registry and significantly lower than ex-
pected in a real-world HF population [7]. The adherence to
recommended therapy in HF was 88% for ACE inhibitors
or ARBs, 87% for beta-blockers, and 44% for MRA, but no
distinction was made between patients with reduced versus
preserved LVEF regarding therapy [7]. Moreover, there is
limited available information on dosage, which will be an
important strength of CHECK-HF. The ESC-HF long-term
registry (ESC-HF-LT) was a prospective, observational reg-
istry in 211 cardiology centres from 21 European and/or
Mediterranean countries, all being member countries of the
ESC [8]. Between May 2011 and April 2013, it collected
data on 12,440 patients, 40.5% of them hospitalised with
acute HF and 59.5% outpatients with chronic HF. Thus, the
ESC-HF-LT registry evaluated 7,401 patients with chronic
HF with a mean age of 66 years and 28.8% female pa-
tients. Again, these figures are much lower compared with
the current real world HF registry in CHECK-HF [8, 9].
The mean EF was 35%. Overall adherence to HF med-
ication was high with 89% for ACE inhibitors, 88% for
beta-blockers, and 59% for MRA, but again no information
on appropriateness of their use. The ARNO Observatory
study by the Italian National Health Service (INHS) con-
sisted of 41,413 patients who were discharged for HF from
1 January 2008–31 December 2012 and prescribed at least
one HF treatment [18]. ACE inhibitors/ARBs, beta-block-
ers, and mineralocorticoid antagonists were prescribed in
65.8%, 49.7%, and 42.1% of patients respectively. During
1-year follow-up, at least one rehospitalisation occurred in
56.6% of patients, 49% of them due to non-cardiovascular
causes [18].
Strengths of the CHECK-HF registry
Overall, the CHECK-HF registry has several strengths. The
CHECK-HF registry is one of the largest of its kind with
almost 11,000 patients included. Moreover, it reflects actual
real-world care as performed on outpatient HF clinics with
a larger proportion of females and elderly when compared
with other registries and clinical trials in particular, which
better represents actual daily practice in many hospitals.
The CHECK-HF registry has detailed information on med-
ication use and dosage. The CHECK-HF registry also has
information on co-morbidity levels and some biomarkers.
Because there is extensive detailed information available,
the CHECK-HF registry can provide more insight in rela-
tively large subgroups of patients with HFpEF or HFmrEF
and specific subsets of patients with atrial fibrillation and
heart failure. A limitation of our study is the lack of de-
tailed follow-up data. We plan to collect longitudinal data
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in the near future to report on the quality of HF care in the
Netherlands and intend to perform several cross-sectional
follow-ups of outpatient clinics in the Netherlands, with the
perspective of repeated analyses of CHECK-HF as a long-
term HF care research project. Longitudinal post-hoc data
can potentially be obtained from mortality data from Dutch
national archives (Statistics NL – CBS).
In conclusion, the CHECK-HF registry is a large HF
registry which enrolled nearly 11,000 unselected patients
with chronic HF treated at an outpatient clinic setting in
the Netherlands to evaluate current HF management in
2013–2016 in a real-world setting. Specific attention will
be given to gender and age differences and level of co-mor-
bidities regarding HF treatment and guideline adherence in
future analyses.
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